We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

By LabMedica International staff writers
Posted on 17 May 2022
Print article
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of breath and cognitive slowing.

Acute COVID-19 is strongly linked with increased risk of thrombosis; a prothrombotic state, quantified by elevated Von Willebrand Factor (VWF) Antigen (Ag):ADAMTS13 ratio, and is associated with severity of acute COVID-19 infection. Acute SARS-CoV-2 infection generates a hypercoagulable state, particularly evident in hospitalized patients.

Hematologist at the University College London Hospitals NHS Foundation Trust (London, UK) and their colleagues assessed 330 patients in an outpatient post-COVID clinic between July 2020 and May 2021. Referral to the post COVID clinic included both patients post hospitalization and referrals from community non-hospitalized cases. The median age of the cohort was 46 years (range 18-88 years). Patients followed up in the clinic varied from 3 to 15 months post proven or presumed COVID-19 infection. The majority (97%) of the patients had symptoms greater than three months following acute COVID-19 infection, of which respiratory symptoms and fatigue were the most common symptoms.

ADAMTS13 activity was measured using FRETS VWF73 assay. Von Willebrand screen (VWF antigen and VWF activity) was measured using standard automated immunoturbimetric assay in a Sysmex CS-2500 analyzer (Sysmex UK, Milton Keynes, UK) with a Siemens kit (VWF:Ag and INNOVANCE VWF activity (Siemens Healthcare Diagnostics, Marburg, Germany), and a clotting based assay using Factor VIII (FVIII) deficient plasma and Dade Actin FS Activated PTT reagent was used to measure FVIII. All analysis was performed on plasma derived from peripheral blood samples collected in sodium citrate tubes, as part of routine assessment in the post COVID clinic which included D-dimer.

The investigators reported that overall, 85 (26%) patients had high factor VIII ranging from 2.1 to 5.1 IU/mL, while 60 (18%) patients had high VWF(Ag) ranging from 1.7-3.3 IU/mL. ADAMTS13 activity ranged from 68.2 to 159.3 IU/dL. The median VWF(Ag):ADAMTS13 ratio was 1.2 (interquartile range [IQR] 0.9-1.5) across the cohort, with an elevated VWF(Ag):ADAMTS13 ratio (≥ 1.5) being observed in 92 patients (28%) across the cohort. Community-managed (83%) and hospitalized patients (16%) had a comparable median VWF(Ag):ADAMTS13 ratio of 1.2. Meanwhile, D-dimer was elevated (>550 µg/L FEU) in 42 (13%) patients.

The authors concluded that their findings suggest an ongoing prothrombotic state in PCS, demonstrated by measurable laboratory and clinical parameters, therefore adding confirmation to the hypothesis of microvascular/endothelial dysfunction in the pathogenesis of PCS. They hypothesized the persistence of a hypercoagulable state which may be associated with endothelial dysfunction and microthrombi in the capillary bed of large muscles, causing a reduction in oxygen capacity during exercise, resulting in anaerobic respiration and fatigue. The study was published on May 11, 2022 in the journal Blood Advances.

Related Links:
University College London Hospitals NHS Foundation Trust 
Sysmex UK 
Siemens Healthcare Diagnostics 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more